CRISPR Therapeutics to Participate in Three June Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present at three conferences in June 2018.
The 2018 BIO International Convention
Panel: Advances in Genome Editing – The Next Frontier in Human Health
Date: Wednesday, June 6, 2018
Presentation: 1:45 – 2:45 PM EST
Location: Room 210 B, Level 2, Boston Convention and Exhibition Center
Goldman Sachs 39th Annual Global Healthcare Conference
Date: Wednesday, June 13, 2018
Fireside Chat: 8:00 – 8:35 AM PST
Location: Terranea Resort, Rancho Palos Verdes, CA.
The JMP 2018 Securities Life Sciences Conference
Panel: Gene Editing: From Science to Reality
Date: Wednesday, June 20, 2018
Presentation: 8:00 – 8:50 AM EST
Location: The St. Regis Hotel, New York, NY
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit .
MEDIA CONTACT:
Jennifer Paganelli
WCG on behalf of CRISPR
INVESTOR CONTACT:
Chris Erdman
+1 617.307.7227
Chris Brinzey
Westwicke Partners for CRISPR
